TeleRanked

Run a telehealth clinic? Claim your profile on TeleRanked.

Access

DEA's Telemedicine Special Registration Rule Sits in White House Review as Controlled-Substance Prescribing Flexibilities Near a December 31 Expiration

The DEA's final rule for a telemedicine special registration has been pending White House review at OMB since August 25, 2026. The current flexibilities that let clinicians prescribe controlled medications online without a prior in-person exam expire December 31, 2026. Here is where the rule stands and what a lapse would mean.

The TeleRanked Editors·Updated November 12, 2026·8 min read

Quick answer

The DEA's final rule creating a special registration for prescribing controlled substances by telemedicine has been under White House review at OMB's Office of Information and Regulatory Affairs since August 25, 2026, and was still listed as pending as of November 12, 2026. The pandemic-era flexibilities that let clinicians prescribe Schedule II to V controlled medications by telemedicine without a prior in-person exam expire December 31, 2026 under a fourth temporary extension. Unless the DEA finalizes the rule or issues another extension, that prescribing pathway would generally lapse on January 1, 2027.

Key takeaways

  • →The DEA sent its final rule, Special Registrations for Telemedicine and Limited State Telemedicine Registrations (RIN 1117-AB40), to OMB's Office of Information and Regulatory Affairs on August 25, 2026, and it remained listed as pending review as of November 12, 2026.
  • →The current telemedicine prescribing flexibilities for controlled medications expire December 31, 2026 under the Fourth Temporary Extension that the DEA and HHS issued on December 31, 2025 (90 FR 61301).
  • →The January 2025 proposed rule would create three special registrations and new prescription, recordkeeping, and reporting duties. It is proposed, not final, and the final rule's text is not public.
  • →If the flexibilities lapse without a final rule or a further extension, telemedicine prescribing of controlled substances would generally revert to the Ryan Haight Act's in-person evaluation requirement on January 1, 2027.
  • →The DEA and HHS have extended these flexibilities four times. A fifth extension is a possible fallback, but none has been announced.

A regulatory deadline that affects how millions of patients get prescriptions for ADHD stimulants, buprenorphine for opioid use disorder, and testosterone is seven weeks away, and the rule meant to resolve it is not yet public. The DEA's long-awaited final rule to create a special registration for telemedicine prescribing of controlled substances has been sitting in White House review since late August 2026, while the temporary flexibilities that currently allow that prescribing are set to expire December 31, 2026.

Where the rule stands right now

On August 25, 2026, the DEA submitted its final rule, titled Special Registrations for Telemedicine and Limited State Telemedicine Registrations, to the Office of Information and Regulatory Affairs (OIRA) within the Office of Management and Budget. OIRA review is the last formal step before a final rule can be published in the Federal Register. As of November 12, 2026, the government's own review tracker still listed the rule (RIN 1117-AB40) as pending review, with no conclusion date and no published final text. No final rule under this docket has appeared in the Federal Register.

Because the rule is still under review, its final contents are not public. The proposal that preceded it is on the record, but the DEA can change provisions between the proposed and final stages, so the specifics below describe what was proposed, not what the agency has decided.

The December 31 cliff

The ability to prescribe controlled substances by telemedicine without a prior in-person exam rests on temporary flexibilities first adopted during the COVID-19 public health emergency. The DEA and HHS have renewed them repeatedly. The most recent renewal, the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (90 FR 61301), was issued December 31, 2025 and is effective from January 1, 2026 through December 31, 2026. It lets registered practitioners prescribe Schedule II to V controlled medications through telemedicine without first conducting an in-person medical evaluation.

Those flexibilities are an exception to the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which generally requires at least one in-person medical evaluation before a practitioner may prescribe a controlled substance. The special registration pathway is the permanent mechanism Congress authorized in that statute, and it is the framework the pending rule is meant to build out.

What the proposed special registration would do

The DEA's proposed rule, published January 17, 2025 (90 FR 6541), would establish a Special Registration framework and authorize three registration types. The comment period closed March 18, 2025.

  • A Telemedicine Prescribing Registration, which would let qualifying clinician practitioners prescribe Schedule III to V controlled substances by telemedicine.
  • An Advanced Telemedicine Prescribing Registration, which would extend to Schedule II to V and was aimed at specified practitioners such as psychiatrists and hospice physicians.
  • A Telemedicine Platform Registration, a first-of-its-kind requirement that direct-to-consumer telemedicine platforms register with the DEA.

The proposal also set out heightened prescription, recordkeeping, and reporting requirements, which commenters flagged as operationally heavy. Whether the final rule keeps the platform registration or softens those duties is not known while the rule is under review.

What a lapse on January 1 would mean

If December 31, 2026 passes without a published final rule or a further extension, the statutory default returns: a practitioner would generally need an in-person evaluation before prescribing a controlled substance, with only the narrow telemedicine exceptions that predate the pandemic flexibilities. The practical reach is wide. Stimulants for ADHD are Schedule II, buprenorphine for opioid use disorder in addiction treatment is Schedule III, and testosterone used in hormone therapy is Schedule III, so a lapse would touch several of the most common telehealth prescribing lines at once.

The DEA and HHS have avoided that outcome before by extending the flexibilities, most recently through the fourth extension. A fifth extension would be the obvious fallback if the final rule is not ready, and the agencies have used short bridging extensions as a transition tool in the past. As of now, no fifth extension has been proposed or announced.

Why the timing is tight

OIRA review has no fixed clock, and a rule can stay pending for weeks or months. Even after review concludes, the DEA could set an effective date later than the publication date or phase in registration requirements, which means a final rule landing in December would not necessarily switch on an immediate new regime. The federal regulatory agenda had listed late 2026 as a target for final action, but an agenda date is an estimate, not a binding deadline. The combination of a hard statutory expiration on December 31 and a final rule still inside White House review is what makes the next several weeks consequential for telehealth prescribers and the patients who depend on them.

What this means for patients and clinicians

This is general information, not medical or legal advice. For people who currently receive a controlled-substance prescription through telehealth, a few reasonable steps while the process plays out:

  • Ask your prescriber or telehealth platform how they plan to handle continuity of care if the flexibilities change at year end, including whether an in-person visit may be needed.
  • Do not let a prescription lapse unexpectedly: confirm refill timing and any required appointments well before December 31.
  • Watch the Federal Register and the DEA for either a published final rule or a further extension, which is where a binding change would actually appear.
  • Treat secondhand summaries, including headlines that describe the rule as already finalized, with caution until the official text is posted.

Frequently asked questions

Has the DEA finalized the telemedicine special registration rule?+

No. As of November 12, 2026 the final rule was under review at OMB's Office of Information and Regulatory Affairs, where the DEA submitted it on August 25, 2026. No final text has been published in the Federal Register.

When do the current telemedicine prescribing flexibilities expire?+

December 31, 2026. The Fourth Temporary Extension (90 FR 61301), issued December 31, 2025, runs from January 1, 2026 through December 31, 2026 and allows telemedicine prescribing of Schedule II to V controlled medications without a prior in-person exam.

What happens to telemedicine prescriptions on January 1, 2027?+

If the flexibilities expire without a final rule or a further extension, prescribing of controlled substances would generally revert to the Ryan Haight Act's in-person evaluation requirement. Whether that happens depends on whether the DEA finalizes the rule or issues another extension before year end.

What are the three special registrations the DEA proposed?+

In the January 2025 proposed rule, a Telemedicine Prescribing Registration for Schedule III to V, an Advanced Telemedicine Prescribing Registration for Schedule II to V aimed at specified practitioners, and a Telemedicine Platform Registration for direct-to-consumer platforms. These are proposals; the final rule's contents are not public.

Which treatments would a lapse affect most?+

Lines that rely on controlled substances prescribed by telehealth, including stimulants for ADHD (Schedule II), buprenorphine for opioid use disorder (Schedule III), and testosterone used in hormone therapy (Schedule III).

Could the DEA issue another extension instead?+

It is possible. The DEA and HHS have extended these flexibilities four times and have used short bridging extensions before. As of November 12, 2026, no fifth extension had been proposed or announced.

Sources

  1. 1.Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (90 FR 61301) · Federal Register (DEA/HHS)
  2. 2.Special Registrations for Telemedicine and Limited State Telemedicine Registrations, Proposed Rule (90 FR 6541) · Federal Register (DEA)
  3. 3.OIRA review record for RIN 1117-AB40, Special Registrations for Telemedicine (Pending Review, received 08/25/2026) · Office of Information and Regulatory Affairs, OMB
  4. 4.DEA Appears Close to Finalizing Telemedicine Special Registration · McDermott Will & Schulte
  5. 5.DEA Telemedicine Special Registration Final Rule Sent to OIRA · Frier Levitt

Related